Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.

Abstract

Ninety-seven patients less than or equal to 70 years of age with previously untreated primary acute myeloblastic leukemia were randomly treated with either the DAT or TAD regimen: daunorubicin (70 mg/m2/day) administered on Days 1-3 (DAT) or 5-7 (TAD) of a 7-day sequence consisting of cytarabine (200 mg/m2/day) and 6-thioguanine (200 mg/m2/day). Complete responders received consolidation, maintenance, and final intensification over 14 months using mostly the same drugs as during induction and administered in the same sequence. The regimens did not significantly differ from each other with regard to toxicity or efficacy. Complete remission rate was 80% in the two groups, and median duration of complete remission was 549 days with DAT and 518 days with TAD.

• Authors: E Archimbaud, D Fiere, D Treille-Ritouet, P Adeleine, D Guyotat, C Sebban, H Vuvan, J J Viala
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 71 Issue 6 Pg. 571-4 (Jun 1987) ISSN: 0361-5960 [Print] United States
• PMID: 3555788 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Cytarabine
• Thioguanine
• Daunorubicin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Cytarabine (administration & dosage)
• Daunorubicin (administration & dosage)
• Drug Administration Schedule
• Female
• Humans
• Leukemia, Myeloid, Acute (drug therapy)
• Male
• Middle Aged
• Random Allocation
• Statistics as Topic
• Thioguanine (administration & dosage)